申请人:Eisai Co., Ltd.
公开号:US05554615A1
公开(公告)日:1996-09-10
A novel pyrimidine derivative having an excellent antitumor activity, which is represented by the following general formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein R.sup.1 represents a hydroxyl or amino group; R.sup.2 represents a phenylene, pyridinediyl, thiendiyl, furandiyl or thiazoldiyl group, --CO.sub.2 R.sup.5 and --CO.sub.2 R.sup.6 may be the same or different from each other and each represents a carboxyl group or a carboxylic acid ester, the part ##STR2## A represents an oxygen atom, a group represented by the formula: ##STR3## (wherein R.sup.3 and R.sup.4 may be the same or different from each other and each represents a hydrogen or halogen atom or a hydrocarbon group which may be substituted, or alternatively R.sup.3 and R.sup.4 may be united to form an alkylidene group which may be substituted) or a group represented by the formula: ##STR4## (wherein R.sup.70 represents a hydrogen atom or a hydrocarbon group), and n is an integer of 1 to 3, provided that the compound in which R.sup.1 represents oxygen, and hydrogen is attached to nitrogen at 3-position is included in the above shown definition, a process for preparation the same, and an antitumor drug containing the same.
一种具有优异抗肿瘤活性的新型嘧啶衍生物,其由以下一般式(I)或其药理学上可接受的盐所代表:##STR1## 其中R.sup.1代表一个羟基或氨基团;R.sup.2代表苯基、吡啶基、噻吩基、呋喃基或噻唑基团,--CO.sub.2R.sup.5和--CO.sub.2R.sup.6可以相同也可以不同,每个代表一个羧基或羧酸酯,部分##STR2## A代表氧原子,一个由式表示的基团:##STR3## (其中R.sup.3和R.sup.4可以相同也可以不同,每个代表氢或卤素原子或一个可被取代的碳氢基团,或者R.sup.3和R.sup.4可以结合形成一个可被取代的烷基亚甲基)或一个由式表示的基团:##STR4## (其中R.sup.70代表氢原子或一个碳氢基团),n是1到3的整数,前提是在上述定义中包括R.sup.1代表氧,氢附着在3-位置的氮化合物,一种制备该化合物的方法,以及含有该化合物的抗肿瘤药物。